Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-590: Pembrolizumab in Advanced Esophageal Carcinoma
NCT03189719Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
A Phase 3 trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03189719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189719.